Agilent Technologies, Inc. · NYSE:A
Agilent Technologies — Q1 2026 Earnings Presentation
10 slides from Agilent Technologies's earnings presentation, Feb 25, 2026
Slide 1: 1Q FY2026 Financial Results Overview
1Q FY2026 FINANCIAL RESULTS OVERVIEW February 25, 2026
Slide 2: Safe Harbor
Thank You for Your Attention Safe Harbor This presentation contains forward- successfully adapt its cost structures to The company assumes no obligation to looking statements (including, without continuing changes in business update the information in these limitation, information, and future condit
Slide 3: Agilent 1Q26 Results
Agilent 1Q26 Results High-single digit growth across 3 largest end markets; $ Excellent replacement cycle momentum w/ high- single digit LC growth • Revenue of $1.80B while absorbing ~$10M impact from late Revenue Operating Margin EPS $1.80B 24.6% $1.36 (2) (2) January winter storm in the US • Opera
Slide 4: Q1 results by business group (LDG, ACG, AMG)
Q1 results LDG +3% • LC replacement cycle continues with high-single digit growth Core Growth(1)(2) • Omnis family expansion supporting 16.0% led by ACG Operating Margin(2) +5% Reported high-single digit Cancer Dx growth A solid start to the year in ACG +6% • Altura Ultra Inert LC column launch driv
Slide 5: Geography and product type growth
GEOGRAPHY PRODUCT TYPE Strong growth in Asia, Americas stable trends in Europe; 38% of Agilent Revenue(2) 4% (1) 9% (1) Americas impacted by 1% Europe (1) 29% of Agilent Revenue(2) late January winter GROWTH GROWTH GROWTH Asia-Pacific storm 33% of Agilent Revenue(2) (1) Core growth is reported growt
Slide 6: Q1 revenue mix
GEOGRAPHY PRODUCT TYPE % of total revenue Q1 revenue mix 63% Consumables Services Replacement cycle strength Informatics drives increasing Instruments 37% contribution Instruments 06
Slide 7: High-single digit growth in our 3 largest end markets
Q1 Core Share Growth(1) of Agilent Results Revenue(2) +7% 36% Double-digit growth in biotech, ~50% GLP-1 growth Pharma across specialty CDMO and analytical lab businesses Q1 REVENUE Diagnostics & High-single digit +7% 15% Expanded Omnis family driving new customer Clinical interest in medium through
Slide 8: FY26 Guidance
Net $7.3B $7.5B FY26 Guidance Revenue ($) (1) Core Revenue Maintaining core Growth(2) +4% +6% (2) +1.5% FX revenue growth & margin expansion; Operating Margins +75 bps YoY & +10% growth at midpoint increasing EPS due to FX EPS $5.90 $6.04 FX adds +$0.04 at midpoint versus prior guide $22M Net Intere
Slide 9: 2Q26 Guidance
2Q26 Guidance (1) Net Revenue ($B) $1.785B $1.815B Continued MSD+ Core Revenue +4% +5.5% growth expected in Growth(2) +3.2% FX largest end markets EPS $1.39 $1.42 $5M Net Interest + Other Inc/(Exp) 283M Share Count Q2 Q2 (1) As of February 25, 2026, based on forecasted currency exchange rates. Prese
Slide 10: Get in touch with us
Get in touch with us Trusted Answers investor_relations@agilent.com www.investor.agilent.com